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Background: To report our early experience with carbon ion irradiation in the treatment of gross residual or
unresectable malignant peripheral nerve sheath tumors (MPNST).
Methods: We retrospectively analysed 11 patients (pts) with MPNST, who have been treated with carbon ion
irradiation (C12) at our institution between 2010 and 2013. All pts had measurable gross disease at the initiation of
radiation treatment. Median age was 47 years (29-79). Tumors were mainly located in the pelvic/sacral (5 pts) and
sinunasal/orbital region (5 pts). 5 pts presented already in recurrent situation, 3 pts had been previously irradiated,
and in 3 pts MPNST were neurofibromatosis type 1 (NF1) associated. Median cumulative dose was 60 GyE.
Treatment was carried out either as a combination of IMRT plus C12 boost (4 pts) or C12 only (7 pts).
Results: Median follow-up was 17 months (3-31 months). We observed 3 local progressions, translating into estimated
1- and 2-year local control rates of 65%. One patient developed distant failure, resulting in estimated 1- and 2-year PFS
rates of 56%. Two patients have died, therefore the estimated 1- and 2-year OS rates are 75%. Acute radiation related
toxicities were generally mild, no grade 3 side effects were observed. Severe late toxicity (grade 3) was scored in 2
patients (trismus, wound healing delays).
Conclusion: Carbon ion irradiation yields very promising short term local control and overall survival rates with low
morbidity in patients suffering from gross residual or unresectable malignant peripheral nerve sheath tumors and
should be further investigated in a prospective trial.Background
Malignant peripheral nerve sheath tumors (MPNSTs)
comprise a rare group of tumors that arise from differ-
ent cells found in the sheath of peripheral nerves includ-
ing Schwann cells, perineural fibroblasts or fibroblasts,
formerly known as malignant schwannoma, neurofibro-
sarcoma, neurogenic sarcoma or malignant neurilemoma
[1]. The reported incidence is 1:1000000 per year [2],
representing 5-10% of all malignant soft tissue tumors
[3]. The most important risk factor is neurofibromatosis
type I (NF I), which accounts for about half of the cases
[1]. The incidence seems equal in males and females and* Correspondence: alexdjensen@gmx.de
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unless otherwise stated.the most common age at diagnosis is 20 to 50 years [2].
Predominant sites of presentation are the proximal ex-
tremities and the pelvis [4]. They usually present as en-
larging mass, which may be associated with pain or
neurological symptoms [2]. However, MPNSTs are
highly aggressive tumors characterized by rapid, infiltrat-
ing growth and hematogenous dissemination [1]. The
preferred modality for imaging of MPNSTs is MRI [5]
for the primary lesion and CT chest to exclude pulmon-
ary metastases [6].
Complete resection with negative margins remains the
mainstay of treatment but frequently results in func-
tional deficits due to the inherent necessity to sacrifice
the involved peripheral nerves [7]. Even after micro-
scopic complete resection, local recurrence rates still ap-
proach 20-38% [3,4,8], which is even increasing in theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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positive margins/gross residual disease, recurrent situ-
ation at presentation or head and neck as initial presen-
tation site [4]. Therefore, neoadjuvant or adjuvant
radiation is commonly used as generally recommended
in high grade soft tissue sarcomas [2,9]. If complete sur-
gical resection seems impossible due to vital adjacent
structures or would result in inacceptable functional def-
icits, primary definitive radiation therapy can be an alter-
native in selected cases [10]. Due to the relatively low
radiation sensitivity of these tumors, doses approaching
70 Gy are needed in conventional fractionated photon
therapy in order to achieve long-term local control in
the presence of gross residual disease [10]. Application
of these doses would result in considerable acute and
late toxicity, and therefore cannot be achieved very often
[10]. Especially in cases with directly adjacent radiosensi-
tive structures, charged particles such as protons or car-
bon ions can offer superior dose distributions even
compared to sophisticated photon techniques [11]. Fur-
thermore, carbon ions seem to have a higher relative
biological effectiveness (RBE) compared to photons or
protons, which may result in increased efficacy as shown
in other radioresistant diseases [11]. For these reasons,
patients with unresectable or incompletely resected
MPNSTs were offered carbon ion treatment at our insti-
tution. Here we report our first experience.
Methods
The medical records of 11 consecutive patients with
MPNST treated with carbon ion radiation in our institu-
tion between 2010 and 2013 were reviewed. Median age
was 47 years (range 29 – 79 years) and 6 patients were
male. Tumors were located in the pelvic/sacral (5), sinu-
nasal/orbital (5) and cervical region (1). Disease was his-
tologically confirmed in all patients. Eight patients had
been surgically treated by partial resection, while 3 pa-
tients received biopsy only. Measurable gross disease
was present in all patients prior to radiation therapy.
Two patients had received induction chemotherapy with
adriamycin/ifosfamide, but no systemic therapy was ap-
plied concurrently to radiation. Five patients presented
already in recurrent situation, 3 of whom had been pre-
viously irradiated. All except one patient showed high
grade lesions. MPNST was neurofibromatosis type 1
(NF1) associated in 3 patients.
Initial work-up included at least clinical examination,
MRI of the primary lesion and CT chest. Patients were
immobilized with a thermoplastic head mask or a vacuum
pillow in supine position. Treatment planning was based
on contrast-enhanced CT (3 mm slice thickness) in cor-
relation with MRI. The first three patients were treated
with combination of photons (IMRT or Tomotherapy)
and carbon ions, while the following 8 patients weretreated with carbon ions only. The GTV included all vis-
ible gross disease. The CTV for the carbon ion treatment
included the GTV with a safety margin of 3 to 5 mm. In
cases with involvement of paranasal sinus all surgically
targeted sinus were included into the CTV. Another 3
mm were added to generate the PTV. Margins could be
reduced at anatomical borders or to spare directly adja-
cent radiosensitive organs (i.e. spinal cord, optic system)
at risk at the discretion of the treating physician. In com-
bination treatments, a second PTV (PTV2) was generated
with a margin of 5 cm along typical pathways of spread. In
the head and neck, the PTV2 included typical compart-
ments, but could not be extended to 5 cm due to proxim-
ity of critical structures. Treatment planning for carbon
ion therapy was performed using TPS© Siemens planning
software for inversely planned, intensity-controlled carbon
ion therapy in raster-scanning technique [12]. Biological
effectiveness of the particle beam was incorporated in the
planning software baseline according to the Local Effects
Model (LEM) [13]. The total dose was prescribed to the
median of the PTV and yielded photon Gray equivalent
(GyE). No further calculations were needed to take ac-
count of the increased biological effectiveness of carbon
ion beams. Note that variations in the biological effective-
ness due to changes in fractionation size are not included
in this model, doses need to be converted according to the
standard LQ model. Treatment planning aims for cover-
age of the CTV by the 95% and the PTV by the 90% iso-
dose according to ICRU 83 [14] . Carbon ion therapy was
clinically available at the HIT facility for 5-6 days per
week.
All patients with combined treatment received 50 Gy
photon IMRT in 25 fractions and 24 GyE carbon ions in
8 fractions. Total cumulative dose in these cases is 74
GyE corresponding to 80 Gy BED. Patients receiving
carbon ions only were treated to total doses of 60 - 66
GyE in 20-22 fractions (median 60 GyE). Patients who
have had prior radiation therapy were re-irradiated with
54-60 GyE in 18-20 fractions. Carbon ion radiation was
applied in intensity-controlled raster-scanning technique
(active beam application) using one to three treatment
angles (median: 2) as described in detail earlier [15]. Ex-
amples of three dimensional dose distributions for pa-
tients with tumors located in the paranasal sinus and
sacral region are shown in Figure 1 and 2.
Regular follow up took place at our institution or the
referring center including at least clinical examination
with scoring of toxicity and MRI of the primary lesion
every 3 months for the first two years and every 6
months thereafter. CT chest was performed at least
every second visit. In case of clinical evidence of local re-
currence or distant spread, additional tests or imaging
modalities were performed to confirm or exclude disease
progression at the discretion of the treating physician.
Figure 1 Example for a dose distribution in a patient with paranasal MPNST (3-field IMPT).
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v4.0. Time to event data was calculated from the first
day of irradiation until the last follow up information or
until death using the Kaplan-Meier method. Locoregio-
nal control was defined as the absence of tumor re-
growth in the region of the treated lesion on repeatedFigure 2 Example for a dose distribution in a patient with sacral MPNST (2MRI scans based on best response after treatment.
Progression-free survival was defined as absence of local
or distant progression or death of any cause. No sub-
group analyses were performed due to the small sample
size. This work is in accordance with the Declaration of
Helsinki in its most recent version. Retrospective-field IMPT).
Figure 3 Local control, progression-free survival and overall survival (entire cohort).
Table 1 Acute radiation related toxicity
Acute toxicity °I °II
(CTCAE v.4) (x/11 pts) (x/11 pts)
Dermatitis 4 1
Dysphagia 1
Dysgeusia 2
Xerophthalmia 3
Conjunctivitis 1
Trigeminus neuralgia 1
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ethics committee (S-141/2014). All patients gave written
informed consent prior to initiation of treatment.
Results
The median follow-up for the entire cohort was 17
months (3-31) and 19 months in surviving patients. We
observed 3 local progressions so far, translating into esti-
mated 1- and 2-year local control rates of 65% (see
Figure 3). One of the recurrences was clearly in-field
while 2 were located at the borders of the high-dose
area. Two out of five patients (40%) in recurrent situ-
ation and one out of 6 patients (17%) in primary situ-
ation developed local progressions. One patient with
local progression had been previously irradiated. One
additional patient developed distant failure. Overall, 4
patients showed local or distant disease progression. The
estimated 1- and 2-year progression-free survival rates
were 56% (see Figure 3). Two patients have deceased so
far, both disease-related. The resulting estimated 1- and
2-year overall survival rates were 75% (see Figure 3).
Maximum acute radiation related side effects were
grade 1 in five patients and grade 2 in one patient,
mainly dermatitis and xerophthalmia. No grade 3 acute
radiation related toxicities were observed. For detailed
acute toxicity see Table 1. Severe late toxicities (grade 3)
were scored in 2 patients, one suffered from trismus
after primary treatment of a large lesion located in the
sphenoid sinus with involvement of the cavernous sinus
(and one from visual impairment). The other patient had
undergone partial resection of a large sacral MPNST. In
view of the tumor’s aggressive growth pattern and prior
radiotherapy, it was decided to start radiotherapy as
early as possible following interdisciplinary discussion.Unfortunately but not unexpectedly, this patient devel-
oped wound healing delays after re-irradiation of the sa-
cral region. For detailed late toxicity see Table 2.
Discussion
Here we report a retrospective case series of irresectable
or incompletely resected malignant peripheral nerve
sheath tumors treated with carbon ion radiation therapy.
To our knowledge, our work represents the largest series
ever published in peer-reviewed literature focusing espe-
cially on the use of carbon ion therapy in this disease.
With a median follow-up of 17 months, we observed a
crude incidence of local and distant failures of 27% and
9%, respectively, translating into 2-year local control,
progression-free survival and overall survival rates of
65%, 56% and 75%, respectively. These results seem to
be promising given the very unfavourable prognostic fac-
tors in our patient cohort.
The cornerstone of curative intent treatment of
MPNST usually remains complete excision with wide
margins [2]. Even after complete excision, local recur-
rence rates of 20-38% have been reported in large series,
Table 2 Late radiation related toxicity
Late toxicity (CTCAE v.4) x/11 pts
Dermatitis °I 1 pt
Hyperpigmentation °I 1 pt
Visual impairment 1 pt
Delayed wound healing 1 pt
Trismus 1 pt
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ation therapy [3,4,8]. Non-extremity site, recurrent situ-
ation at presentation, and positive margins have been
consistently identified as factors significantly associated
with reduced local control and survival in many series
[3,4,7,8,16,17]. Already the presence of microscopically
positive margins was strongly associated with signifi-
cantly increased local recurrence rates, ranging from
61% to 100 % [3,4,8]. Data on gross residual disease in
resected patients are rare, but outcome was usually very
poor in the small numbers of cases published. For ex-
ample, Minovi et al. [1] reported on 3 cases in their
series of 17 patients with incomplete resections and
gross residual disease. Two of them developed local re-
currences shortly after surgery and all of them finally
died of disease. Sordillo et al. [16] observed only 10 pa-
tients in their series of 165 patients with non-surgical-
treatment, none of them was free of disease at 3 years.
Hruban et al. [18] reported 2 out of 43 patients with
subtotal resections, both developed local recurrences
and died of disease. Wanebo et al. [17] included 9 pa-
tients with gross residual disease in their series of 28 pa-
tients. Median progression-free survival for those was
only 1 month with a 1-year PFS rate of less than 25%
and median overall survival was about 9 months with 1-
and 2-year rates of roughly 40% as estimated from the
survival curves. Ducatman et al. [7] reported on 46 pa-
tients with gross residual disease after surgery, of whom
the majority received additional radiation. These tumors
were mainly located in the head and neck or the retro-
peritoneal/pelvic area, similarly to our cases. The 1-year
and 2-year OS survival rates were 63% and 43% as esti-
mated from survival curves for these patients with no in-
formation given about local control. Given the very
limited data specifically addressing the outcome of
MPNST with gross residual tumor following resection,
larger series including other types of soft tissue sarcoma
treated with photon radiation therapy might serve as a
benchmark. Slater et al. [19] analysed 72 patients treated
with photon irradiation and found 2- and 5-year LC
rates of 39% and 29%, respectively. Tepper et al. [20] de-
scribed a similar 5-year LC rate of 33% in their 51 pa-
tients. Kepka et al. [10] reported a very large series of
112 patients with unresectable sarcomas treated with
photon radiation and found 2-year local control, disease-free survival and overall survival rates of 52%, 33% and
55%, respectively. In our cohort, all patients suffered
from non-extremity tumors, 45% were in recurrent situ-
ation and all had gross residual disease after surgery. Al-
though comparisons between different retrospective
series are always difficult and potentially flawed with
biases, our results seem to compare favourably with the
published series of patients with grossly incomplete re-
sections of MPNST or soft tissue sarcomas, especially
given the presence of unfavourable prognostic factors.
As soft tissue sarcomas including MPNST are gener-
ally thought to be comparatively radioresistant tumors,
high doses are usually recommended even after gross
complete resections. For example Wong et al. [3] ana-
lysed 73 patients with MPNST who received adjuvant
radiation and described a significantly improved 5-year
local control rate of 73% with doses of 60 Gy or more
compared to 50% if doses <60 Gy were applied. This
dose dependency was confirmed by multivariate analysis.
Similar dose effect relationships have been described for
soft tissue sarcomas after gross total resection. For ex-
ample Wolfson et al. suggested [21] that doses above 63
Gy favourably affect survival. Zagars et al. [22] found
improved local control rates for doses between 64 and
68 Gy compared to 60 Gy and Fein et al. [23] demon-
strated improved local control rates if doses of 65 Gy or
more were used. For gross residual disease, even higher
doses have to be attempted to achieve durable local con-
trol at least in a substantial proportion of patients. For
example, Carli et al. [24] recommended doses of 65-70
Gy for gross residual disease based on their findings in
pediatric MPNST. Tepper et al. [20] found a significantly
improved local control rate with doses of more than 64
Gy in a series of unresectable soft tissue sarcoma. Slater
et al. [19] described longer duration of local control after
doses exceeding 65 Gy and Kepka et al. [10] reported
significantly improved local control, disease-free survival
and overall survival rates in unresectable soft tissue sar-
coma patients treated with doses of 63 Gy or more. They
confirmed their results in a multivariate analysis and cal-
culated an improvement of 3% per Gy in the 5-year local
control and overall survival rate. However, possible im-
provements in local control by dose-escalation have al-
ways to be weighed against toxicity and functional
outcome. For example Mundt et al. [25] observed a se-
vere complication rate of 0% for doses < 63 Gy compared
to 23% with doses exceeding 63 Gy in grossly resected
soft tissue sarcomas. Stinson et al. [26] also described
significantly worse functional outcomes for doses of
more than 63 Gy. Kepka et al. [10] described a major
complication rate of 8% for doses less or equal to 68 Gy
compared to 27% for doses exceeding 68 Gy in unresect-
able soft tissue sarcomas, and Slater et al. [19] observed
5 of 6 severe complications in patients who were treated
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prompted several groups including ours to investigate al-
ternative boosting techniques like intraoperative radi-
ation therapy (IORT) or brachytherapy to overcome the
limitations of external beam radiation therapy, especially
in non-extremity regions [3,9,27-32]. For example,
Wong et al. [3] observed significantly improved local
control rates according to univariate and multivariate
analysis of their series of grossly resected MPNSTs, if
IORT or brachytherapy was used as a boosting tech-
nique compared to sole percutaneous adjuvant radiation
therapy. Oertel et al. [33] showed a low toxicity profile
for the combination of IORT with moderate doses of
EBRT while achieving similar 5-year local control rates
after gross incomplete resection of soft tissue sarcomas
as reported with high dose external beam radiation.
However, experience in dose-escalated high-precision
photon techniques is limited: to our knowledge, no data
has been presented on the effect of photon doses ex-
ceeding 70 Gy.
Another possibility to enhance the radiation effect
could be the use of different radiation types like particles
mainly because of their known higher biological effect-
iveness compared to photon irradiation. Therefore sev-
eral groups introduced fast neutrons into the treatment
of soft tissue sarcomas, which resulted in promising
local control rates for gross disease but was accompan-
ied by considerable late toxicities [34,35]. In contrast to
neutrons, charged particles like protons and especially
carbon ions offer not only an increased biological effect-
iveness, but also very conformal dose distributions ap-
plying lower doses to adjacent organs at risk compared
to even the most sophisticated photon techniques as
shown by various dosimetric studies [36]. The superior
dose distribution is mainly based on a unique
phenomenon of charged particles known as the Bragg
peak. In contrast to photons, charged particles enter and
travel through tissue with minimal dose deposition along
their path until a peak of deposition is reached in an
energy-dependent depth. Beyond the so called Bragg
peak, the dose deposition practically falls to zero. These
steep gradients allow for superior sparing of directly ad-
jacent organs at risk [36,37]. In contrast to photons or
protons, carbon ions are additionally characterized by a
high linear energy transfer resulting in different radio-
biological interactions with tumor and normal tissue
with an enhanced relative biological effectiveness. There-
fore carbon ions seem to be a very attractive treatment
option especially for unresectable or incompletely
resected tumors with known radioresistant histology lo-
cated directly adjacent to radiosensitive organs at risk.
The transfer of these theoretical advantages into im-
proved local control rates while consistently maintaining
a very low toxicity profile has already been shown inseveral diseases fulfilling above mentioned criteria, for
example chordoma or chondrosarcoma of skull base or
sacral region [11,15,38]. In our cohort, we also observed
very promising local control rates while the rate of se-
vere toxicities was considerably low, especially if taken
into account, that our median dose of 60 GyE would be
equivalent to about 74 Gy of conventionally fractionated
photon radiation as calculated with the currently avail-
able models.
Clearly our study has some limitations, namely its
retrospective nature, the small sample size and the short
follow up. Nevertheless it shows very promising results
in an unfavourable patient group and therefore adds
valuable information to the existing literature.
Conclusion
Carbon ion irradiation yielded very promising short term
local control and overall survival rates with low morbid-
ity in patients suffering from grossly incomplete or unre-
sectable malignant peripheral nerve sheath tumors and
should be further investigated in a prospective trial.
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